Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

29.61 -0.36 (-1.20%)
Streaming Delayed Price Updated: 1:23 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 27,268,559
Open 30.11
Bid (Size) 29.61 (59)
Ask (Size) 29.62 (30)
Prev. Close 29.97
Today's Range 29.38 - 30.23
52wk Range 25.20 - 37.80
Shares Outstanding 5,606,688,356
Dividend Yield 5.54%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche
Neither is a leader right now, but one of them might be on track to change that. 
Via The Motley Fool
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry. 
Via The Motley Fool

Performance

YTD
-0.40%
-0.40%
1 Month
+6.74%
+6.74%
3 Month
+12.76%
+12.76%
6 Month
+4.59%
+4.59%
1 Year
-21.06%
-21.06%

More News

Read More
Could Pfizer Become a Top Weight Loss Drug Stock? Don't Count on It.
Via The Motley Fool
Check Out What Whales Are Doing With PFE
Via Benzinga
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Via Benzinga
Decoding Pfizer's Options Activity: What's the Big Picture?
Via Benzinga
COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch
Via Benzinga
Exposures COVID-19
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Via Benzinga
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
Via Benzinga
Topics Stocks
Exposures US Equities
Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
Via Benzinga
Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio
Via Benzinga
Pfizer, Cisco, Arch Capital And More: CNBC's 'Final Trades'
Via Benzinga
7 Hated Stocks Set to Make a Major Comeback This Year
Via InvestorPlace
Alnylam Stock Is a Blockbuster Biopharma In the Making
Via InvestorPlace
Time to Pounce: 2 Beaten-Down Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought Right Now
Via The Motley Fool
Current Analysis: Pfizer Inc.
Via Talk Markets
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
Via Benzinga
Exposures COVID-19
Pfizer And Roche Advance On Their Weight Loss Drug Journeys
Via Benzinga
3 Under $50 Stocks to Buy Now: Q3 Edition
Via InvestorPlace
Forget Medical Properties Trust: This High-Yielding Dividend Stock Is a Much Better Buy
Via The Motley Fool
7 High-Yield Dividend Stocks Beating Inflation
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Wall Street's Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Positive News is Driving This Cancer Drug Maker’s Stock Higher
Via MarketBeat
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
Via InvestorPlace
2 Pharma Stocks to Buy Hand Over Fist This Month
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.